ClinicalTrials.Veeva

Menu
R

Research Integrity, LLC | Owensboro, KY

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Obicetrapib
Ezetimibe
Survodutide
BI 456906
Vilaprisan
Inclisiran
sodium

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 6 total trials

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml
Locations recently updated

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

The study was performed to assess the efficacy and safety of Vilaprisan in subjects with uterine fibroids compared to standard of care

Active, not recruiting
Uterine Fibroids
Drug: Vilaprisan (BAY1002670)
Other: Standard of care

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Obicetrapib
Drug: Placebo

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholester...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Dyslipidemias
Drug: Placebo
Drug: Obicetrapib

Trial sponsors

N
Bayer logo
Boehringer Ingelheim logo
Novartis logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems